Literature DB >> 15287943

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.

Jacqueline Boultwood1, Andrea Pellagatti, Fiona Watkins, Lisa J Campbell, Noor Esoof, Nicholas C P Cross, Helen Eagleton, Tim J Littlewood, Carrie Fidler, James S Wainscoat.   

Abstract

The putative tumour suppressor gene gravin is down-regulated in several solid tumours and is implicated in tumorigenesis. We have evaluated the expression levels of the gravin gene in the CD34(+)/blast cells of a range of myeloid malignancies as compared with controls using real-time quantitative polymerase chain reaction (PCR). Gravin was markedly down-regulated in 41 of 41 patients with acute myeloid leukaemia (AML), nine of 10 patients with myelodysplastic syndromes (MDS) and 33 of 33 patients with chronic myeloid leukaemia (CML), of whom 24 were in blast crisis (BC). We have shown that gravin is consistently down-regulated in the CD34(+)/blast cells of myeloid malignancies and may play a role in the molecular pathogenesis of these disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15287943     DOI: 10.1111/j.1365-2141.2004.05067.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Gravin gene expression in acute myeloid leukemia.

Authors:  Mohamed R Mostafa; Raida S Yahia; Hanaa M Abd El Messih; Eman El-Sisy; Doaa M El Ghannam
Journal:  Med Oncol       Date:  2013-03-31       Impact factor: 3.064

2.  Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis.

Authors:  Irwin H Gelman
Journal:  Genes Cancer       Date:  2010-11

3.  Integrated bioinformatic analysis of microarray data reveals shared gene signature between MDS and AML.

Authors:  Zhen Zhang; Lin Zhao; Xijin Wei; Qiang Guo; Xiaoxiao Zhu; Ran Wei; Xunqiang Yin; Yunhong Zhang; Bin Wang; Xia Li
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.